NASDAQ NMS - GLOBAL MARKET · KLRS
+0.73% · +$0.0300 · Vol 81.2K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Kalaris Therapeutics Inc

Kalaris Therapeutics Inc

Biotechnology
$4.15
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
KLRS
Kalaris Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

30/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KLRS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KLRS catalysts
About Kalaris Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2025
Employees
20
Country
US

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.10
Day high
$4.30
Day low
$3.99
Previous close
$4.12
52W high
$10.98
-62.20% from high
52W low
$2.51
19% of range
Market cap
$98.8M
EPS
$-4.1000
Beta
0.93
Shares out
23.8M
Volume
81.2K
0.18× rel vol
Avg volume
460.8K
VWAP
$4.12
Price history computed in-house
1W
+4.80%
1M
+11.26%
3M
-20.35%
1Y
+65.34%
YTD
-50.83%
SMA 50 $4.20 · below
SMA 200 $6.49 · below
52W position 19%

KLRS overview

Veridion Score
30
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KLRS.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KLRS Form 4 filings
Public disclosures

Congress activity in KLRS

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for KLRS in the cached public ledger.

Federal contracts

KLRS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KLRS in this window.
Lobbying spend

KLRS lobbying filings, year to date.

Registered lobbying filings matched to Kalaris Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KLRS in this window.
Loading news for KLRS
Analyst ratings
Sovereign unlock shows live analyst consensus for KLRS.
Options
Sovereign unlock shows live options positioning for KLRS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.